Lv1
18 积分 2024-09-24 加入
Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies
3个月前
已完结
Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies
3个月前
已完结
Nanobodies for inflammatory bowel disease: Miniaturizing solutions
3个月前
已完结
DOP118 A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the p40xTL1A bispecific antibody PF-07261271 in healthy participants
3个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
4个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
4个月前
已完结
Advances in NK cell therapy for multiple myeloma
4个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
4个月前
已完结
Cryo-EM structure of the TL1A-DR3 complex and implications for the treatment of Inflammatory Bowel Disease
4个月前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
4个月前
已完结
皖公网安备34019202002308
